Asia Television Holdings Limited announced that Dr. Clemen Chiang Wen Yuan (Dr. Clemen) has been appointed as an independent non-executive director, a member of each of the audit committee (audit committee), a member of the remuneration committee (remuneration committee) and the nomination committee (nomination committee) of the company, in each case, with effect from 1 June 2022. Dr. Clemen, aged 48, is a chartered fellow of the chartered management institute in the United Kingdom, a chartered marketer and a fellow of the chartered institute of marketing in the United Kingdom, and a chartered wealth manager and a fellow of the global academy of finance & management in the United States of America. Clemen obtained a bachelor of engineering (civil) from the Nanyang Technological University, Singapore in 2000, a master
of business administration from the University of Louisville, United States of America in 2002, and a doctor of philosophy from the University of Canberra, Australia in 2017. Dr. Clemen has rich experience in entrepreneurship, business strategy and fintech. Clemen is the chief executive officer of Aly Pte. Ltd., a financial technology company in Singapore.
Dr. Clemen is currently an independent director and the chairman of the remuneration and nominating committee of Travelite Holdings Ltd. Clemen is also an advisor of the advisory board of SMI Vantage Limited. Dr. Clemen was director of Freely Pte. Ltd. from 19 April 2001 until its dissolution via compulsory winding up (insolvency) on 4 September 2014. Freely Pte. Ltd. was a company in Singapore exempted from holding Capital Markets Services Licence to carry on business in fund management to not more than 30 qualified investors as defined under the securities and futures regulations. In January 2007, Freely Pte. Ltd. was issued a supervisory warning from the monetary authority of Singapore (MAS) for breaching a direction issued by the MAS by stating on its website that freely investments has been awarded a licence by the MAS to manage funds for up to 30 high-net worth individuals, which is in contravention of section
101(1) of the securities and futures act, chapter 289. Save as disclosed above, Dr. Clemen has not held any other directorships in public companies listed in Hong Kong or any other major exchanges in the last three years preceding the date of this announcement. Dr. Clemen is appointed for an initial term of two years, but will retire at the forthcoming general meeting of the company pursuant to article 86(3) of the company's articles of association and shall then be eligible for re-election. Thereafter, Dr. Clemen will be subject to retirement by rotation and re-election every three years at the annual general meetings of the company in accordance with article 87 of the company's articles of association.